Rosiglitazone Versus Rosiglitazone and Metformin (Avandamet) Versus Combination Rosiglitazone and Losartan in the Treatment of Nonalcoholic Steatohepatitis (NASH). A Prospective, Open-Label, Randomized Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT00699036

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:34:58.738912+00:00

Published At

2009-06-19T00:00:00+00:00

Record Updated At

2009-06-19

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Nonalcoholic Steatohepatitis", "Nonalcoholic Fatty Liver Disease"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2009-06-19"

protocolSection.identificationModule.nctId

"NCT00699036"

protocolSection.identificationModule.officialTitle

"Rosiglitazone Versus Rosiglitazone and Metformin (Avandamet) Versus Combination Rosiglitazone and Losartan in the Treatment of Nonalcoholic Steatohepatitis (NASH). A Prospective, Open-Label, Randomized Trial"

protocolSection.statusModule.overallStatus

"UNKNOWN"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Nonalcoholic Steatohepatitis (protocolSection.conditionsModule.conditions)
• Nonalcoholic Fatty Liver Disease (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.